{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T02:53:08Z","timestamp":1794019988002,"version":"4.8.0"},"reference-count":42,"publisher":"Walter de Gruyter GmbH","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,1,26]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background:<\/jats:title><jats:p>The purpose of this study was to evaluate the safety and convenience of initial bisphosphonate infusion therapy in inpatient and outpatient settings for patients with low bone mineral density.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods:<\/jats:title><jats:p>All data were collected from retrospective chart reviews of heterogeneous groups of patients. Abnormal findings prior to the infusion and side effects during the infusion were documented. Patients were contacted following the infusion to discuss post-infusion adverse events.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results:<\/jats:title><jats:p>The majority of both outpatients (80%, n=44) and inpatients (50%, n=27) did not experience any adverse events related to the infusion. Some patients reported minor adverse events that were expected. Only one of the inpatients had a severe adverse event (SAE) after the infusion.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions:<\/jats:title><jats:p>For patients at low risk for severe reactions to treatment, the infusion center appears to be a safe and possibly more convenient treatment setting for both the patient and the hospital, although more expensive for the patient at our institution.<\/jats:p><\/jats:sec>","DOI":"10.1515\/jpem-2016-0318","type":"journal-article","created":{"date-parts":[[2017,9,16]],"date-time":"2017-09-16T10:01:29Z","timestamp":1505556089000},"source":"Crossref","is-referenced-by-count":6,"title":["A retrospective review of initial bisphosphonate infusion in an inpatient vs. outpatient setting for bisphosphonate na\u00efve patients"],"prefix":"10.1515","volume":"30","author":[{"given":"Rose M.","family":"Kreikemeier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Gosnell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa M.","family":"Halbur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric T.","family":"Rush","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","reference":[{"key":"ref401","doi-asserted-by":"crossref","first-page":"119","DOI":"10.3109\/01676830.2011.648818","article-title":"Bisphosphonate-associated orbital inflammation \u2013 a case report and review","volume":"31","year":"2012","journal-title":"Orbit"},{"key":"ref371","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1590\/0104-1169.0372.2637","article-title":"Anxiety in children following hospitalization: a proposal for a nursing diagnosis","volume":"23","year":"2015","journal-title":"Rev Lat Am Enfermagem"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1359\/jbmr.060601","article-title":"Association between bone mass and fractures in children: a prospective cohort study","volume":"21","year":"2006","journal-title":"J Bone Miner Res"},{"key":"ref161","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1590\/0104-1169.0372.2637","article-title":"Anxiety in children following hospitalization: a proposal for a nursing diagnosis","volume":"23","year":"2015","journal-title":"Rev Lat Am Enfermagem"},{"key":"ref41","first-page":"440","article-title":"Bisphosphonate therapy for fibrous dysplasia","year":"2007","journal-title":"Pediatr Endocrinol Rev"},{"key":"ref131","first-page":"63","article-title":"Cyclic pamidronate therapy in children with osteogenesis imperfecta: results of treatment and follow-up after discontinuation","volume":"21","year":"2008","journal-title":"J Pediatr Endocrinol Metab"},{"key":"ref01","first-page":"CD005088","article-title":"Bisphosphonate therapy for osteogenesis imperfecta (Review)","volume":"10","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"ref151","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11914-016-0299-y","article-title":"Advances in the classification and treatment of osteogenesis imperfecta","volume":"14","year":"2016","journal-title":"Curr Osteoporos Rep"},{"key":"ref251","first-page":"440","article-title":"Bisphosphonate therapy for fibrous dysplasia","year":"2007","journal-title":"Pediatr Endocrinol Rev"},{"key":"ref331","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1159\/000365889","article-title":"The use of bisphosphonates in pediatrics","volume":"82","year":"2014","journal-title":"Horm Res Paediatr"},{"key":"ref391","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.bone.2004.03.008","article-title":"Respiratory distress with pamidronate treatment in infants with severe osteogenesis imperfecta","volume":"35","year":"2004","journal-title":"Bone"},{"key":"ref81","doi-asserted-by":"crossref","first-page":"e5","DOI":"10.1542\/peds.110.1.e5","article-title":"Bone density and metabolism in children and adolescents with moderate to severe cerebral palsy","volume":"110","year":"2002","journal-title":"Pediatrics"},{"key":"ref291","doi-asserted-by":"crossref","first-page":"e5","DOI":"10.1542\/peds.110.1.e5","article-title":"Bone density and metabolism in children and adolescents with moderate to severe cerebral palsy","volume":"110","year":"2002","journal-title":"Pediatrics"},{"key":"ref71","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1017\/S0012162206001526","article-title":"Low doses of pamidronate to treat osteopenia in children with severe cerebral palsy: a pilot study","volume":"48","year":"2006","journal-title":"Dev Med Child Neurol"},{"key":"ref361","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11914-016-0299-y","article-title":"Advances in the classification and treatment of osteogenesis imperfecta","volume":"14","year":"2016","journal-title":"Curr Osteoporos Rep"},{"key":"ref271","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1359\/jbmr.060601","article-title":"Association between bone mass and fractures in children: a prospective cohort study","volume":"21","year":"2006","journal-title":"J Bone Miner Res"},{"key":"ref211","first-page":"CD005088","article-title":"Bisphosphonate therapy for osteogenesis imperfecta (Review)","volume":"10","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"ref101","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJM199810013391402","article-title":"Cyclic administration of pamidronate in children with severe osteogenesis imperfecta","volume":"339","year":"1998","journal-title":"N Engl J Med"},{"key":"ref241","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1185\/03007995.2011.645562","article-title":"Long-term outcomes of children and adolescents who had cerebral palsy with secondary osteoporosis","volume":"28","year":"2012","journal-title":"Curr Med Res Opin"},{"key":"ref301","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1136\/adc.86.5.356","article-title":"Beneficial effect of long term intravenous bisphosphonate treatment of osteogenesis imperfecta","volume":"86","year":"2002","journal-title":"Arch Dis Child"},{"key":"ref311","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJM199810013391402","article-title":"Cyclic administration of pamidronate in children with severe osteogenesis imperfecta","volume":"339","year":"1998","journal-title":"N Engl J Med"},{"key":"ref411","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s11832-012-0383-5","article-title":"Complications of pamidronate therapy in paediatric osteoporosis","volume":"6","year":"2012","journal-title":"J Child Orthop"},{"key":"ref261","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1159\/000354303","article-title":"Intravenous zoledronic acid given every 6 months in childhood osteoporosis","volume":"80","year":"2013","journal-title":"Horm Res Paediatr"},{"key":"ref121","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1159\/000365889","article-title":"The use of bisphosphonates in pediatrics","volume":"82","year":"2014","journal-title":"Horm Res Paediatr"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1097\/BPO.0000000000000421","article-title":"Pamidronate treatment to prevent reoccurring fractures in children with cerebral palsy","volume":"36","year":"2016","journal-title":"J Pediatr Orthop"},{"key":"ref231","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1097\/BPO.0000000000000421","article-title":"Pamidronate treatment to prevent reoccurring fractures in children with cerebral palsy","volume":"36","year":"2016","journal-title":"J Pediatr Orthop"},{"key":"ref281","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1017\/S0012162206001526","article-title":"Low doses of pamidronate to treat osteopenia in children with severe cerebral palsy: a pilot study","volume":"48","year":"2006","journal-title":"Dev Med Child Neurol"},{"key":"ref11","first-page":"1846","article-title":"Pamidronate treatment of severe osteogenesis imperfecta in children under 3 years of age","volume":"85","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"ref221","first-page":"1846","article-title":"Pamidronate treatment of severe osteogenesis imperfecta in children under 3 years of age","volume":"85","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1185\/03007995.2011.645562","article-title":"Long-term outcomes of children and adolescents who had cerebral palsy with secondary osteoporosis","volume":"28","year":"2012","journal-title":"Curr Med Res Opin"},{"key":"ref91","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1136\/adc.86.5.356","article-title":"Beneficial effect of long term intravenous bisphosphonate treatment of osteogenesis imperfecta","volume":"86","year":"2002","journal-title":"Arch Dis Child"},{"key":"ref171","doi-asserted-by":"crossref","first-page":"155","DOI":"10.3233\/PRM-140284","article-title":"Respiratory failure during infusion of pamidronate in a 3 year-old male with osteogenesis imperfecta: a case report","volume":"7","year":"2014","journal-title":"J Pediatr Rehabil Med"},{"key":"ref201","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s11832-012-0383-5","article-title":"Complications of pamidronate therapy in paediatric osteoporosis","volume":"6","year":"2012","journal-title":"J Child Orthop"},{"key":"ref111","first-page":"1846","article-title":"Pamidronate treatment of severe osteogenesis imperfecta in children under 3 years of age","volume":"85","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"ref341","first-page":"63","article-title":"Cyclic pamidronate therapy in children with osteogenesis imperfecta: results of treatment and follow-up after discontinuation","volume":"21","year":"2008","journal-title":"J Pediatr Endocrinol Metab"},{"key":"ref141","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1093\/jpepsy\/jsn039","article-title":"Brief report: illness factors and child behavior before and during pediatric hospitalization","volume":"33","year":"2008","journal-title":"J Pediatr Psychol"},{"key":"ref381","doi-asserted-by":"crossref","first-page":"155","DOI":"10.3233\/PRM-140284","article-title":"Respiratory failure during infusion of pamidronate in a 3 year-old male with osteogenesis imperfecta: a case report","volume":"7","year":"2014","journal-title":"J Pediatr Rehabil Med"},{"key":"ref191","doi-asserted-by":"crossref","first-page":"119","DOI":"10.3109\/01676830.2011.648818","article-title":"Bisphosphonate-associated orbital inflammation \u2013 a case report and review","volume":"31","year":"2012","journal-title":"Orbit"},{"key":"ref181","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.bone.2004.03.008","article-title":"Respiratory distress with pamidronate treatment in infants with severe osteogenesis imperfecta","volume":"35","year":"2004","journal-title":"Bone"},{"key":"ref321","first-page":"1846","article-title":"Pamidronate treatment of severe osteogenesis imperfecta in children under 3 years of age","volume":"85","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"ref351","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1093\/jpepsy\/jsn039","article-title":"Brief report: illness factors and child behavior before and during pediatric hospitalization","volume":"33","year":"2008","journal-title":"J Pediatr Psychol"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1159\/000354303","article-title":"Intravenous zoledronic acid given every 6 months in childhood osteoporosis","volume":"80","year":"2013","journal-title":"Horm Res Paediatr"}],"container-title":["Journal of Pediatric Endocrinology and Metabolism"],"original-title":[],"link":[{"URL":"http:\/\/www.degruyter.com\/view\/j\/jpem.2017.30.issue-10\/jpem-2016-0318\/jpem-2016-0318.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/jpem-2016-0318\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,22]],"date-time":"2021-04-22T01:41:34Z","timestamp":1619055694000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/jpem-2016-0318\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1,1]]},"references-count":42,"journal-issue":{"issue":"10"},"URL":"https:\/\/doi.org\/10.1515\/jpem-2016-0318","relation":{},"ISSN":["2191-0251","0334-018X"],"issn-type":[{"value":"2191-0251","type":"electronic"},{"value":"0334-018X","type":"print"}],"subject":[],"published":{"date-parts":[[2017,1,1]]}}}